肾脏移植后抗体介导排斥反应的推荐治疗方法：移植学会工作组的2019年专家共识

2020-05-01 Transplantation . 2020 May;104(5):911-922

随着现代固相检测抗-HLA抗体的发展和更精确的组织学分类，抗体介导的排斥（AMR）的诊断已经越来越普遍，是肾移植丢失的主要原因。目前，还没有被批准的治疗方法，治疗指南也是基于低水平的证据。治疗AMR的

中文标题：

发布机构：

发布日期：

2020-05-01

简要介绍：

随着现代固相检测抗-HLA抗体的发展和更精确的组织学分类，抗体介导的排斥（AMR）的诊断已经越来越普遍，是肾移植丢失的主要原因。目前，还没有被批准的治疗方法，治疗指南也是基于低水平的证据。治疗AMR的前瞻性随机试验数量较少，而且缺乏公认的共同护理标准，一直阻碍着新疗法的发展。为了帮助缓解这一问题，移植协会召开了一次国际专家会议，就什么是活动性和慢性活动性AMR的适当治疗达成共识。其目的是就标准护理治疗达成共识，并据此评估新疗法。会上讨论了AMR的基础生物学、诊断标准、临床表型和结果。会议回顾了不同治疗方法的证据，并就什么是可接受的活动性和慢性活动性AMR治疗标准达成了共识。虽然大家一致认为治疗的目的是保留肾功能，减少组织学损伤，降低供体特异性抗体的滴度，但没有确凿的证据支持任何特定的治疗。因此，治疗建议主要基于专家意见。人们承认，为了改善患者的治疗效果，迫切需要对生物学上可信的药物进行适当的、有动力的临床试验。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=d63d01c00199a342, title=肾脏移植后抗体介导排斥反应的推荐治疗方法：移植学会工作组的2019年专家共识, enTitle=, guiderFrom=Transplantation . 2020 May;104(5):911-922, authorId=0, author=, summary=随着现代固相检测抗-HLA抗体的发展和更精确的组织学分类，抗体介导的排斥（AMR）的诊断已经越来越普遍，是肾移植丢失的主要原因。目前，还没有被批准的治疗方法，治疗指南也是基于低水平的证据。治疗AMR的, cover=, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri May 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<p>随着现代固相检测抗-HLA抗体的发展和更精确的组织学分类，抗体介导的排斥（AMR）的诊断已经越来越普遍，是肾移植丢失的主要原因。目前，还没有被批准的治疗方法，治疗指南也是基于低水平的证据。治疗AMR的前瞻性随机试验数量较少，而且缺乏公认的共同护理标准，一直阻碍着新疗法的发展。为了帮助缓解这一问题，移植协会召开了一次国际专家会议，就什么是活动性和慢性活动性AMR的适当治疗达成共识。其目的是就标准护理治疗达成共识，并据此评估新疗法。会上讨论了AMR的基础生物学、诊断标准、临床表型和结果。会议回顾了不同治疗方法的证据，并就什么是可接受的活动性和慢性活动性AMR治疗标准达成了共识。虽然大家一致认为治疗的目的是保留肾功能，减少组织学损伤，降低供体特异性抗体的滴度，但没有确凿的证据支持任何特定的治疗。因此，治疗建议主要基于专家意见。人们承认，为了改善患者的治疗效果，迫切需要对生物学上可信的药物进行适当的、有动力的临床试验。</p>, tagList=[TagDto(tagId=261, tagName=肾移植)], categoryList=[CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3314, appHits=82, showAppHits=0, pcHits=903, showPcHits=3232, likes=0, shares=9, comments=6, approvalStatus=1, publishedTime=Fri Oct 23 18:08:34 CST 2020, publishedTimeString=2020-05-01, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Oct 23 18:08:27 CST 2020, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 05:20:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])

66.pdf

下载请点击：

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1069487, encodeId=ff06106948e25, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24d05619594, createdName=ms3000000366766127, createdTime=Fri Nov 12 09:02:34 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997961, encodeId=1c7b99e961dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpliahBB2LdGxCRcnBjmrmZvEg8kjSybd5bDqSsQEljwtJOMsOjT6IjU91bX5antfPt5tHIv1kf7TgI/0, createdBy=bb9a2046117, createdName=刘东泽, createdTime=Fri Jul 09 13:24:38 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949322, encodeId=573494932280, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/744f639c0ac24549ab1e0c4fbb6876ed/9afc870f9e0d45a0963b7dae6cc8c8b2.jpg, createdBy=11b55161224, createdName=146b8afcm93(暂无昵称), createdTime=Thu Mar 18 19:51:40 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917595, encodeId=961b91e59517, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:23 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
2021-11-12 ms3000000366766127

学习了

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1069487, encodeId=ff06106948e25, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24d05619594, createdName=ms3000000366766127, createdTime=Fri Nov 12 09:02:34 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997961, encodeId=1c7b99e961dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpliahBB2LdGxCRcnBjmrmZvEg8kjSybd5bDqSsQEljwtJOMsOjT6IjU91bX5antfPt5tHIv1kf7TgI/0, createdBy=bb9a2046117, createdName=刘东泽, createdTime=Fri Jul 09 13:24:38 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949322, encodeId=573494932280, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/744f639c0ac24549ab1e0c4fbb6876ed/9afc870f9e0d45a0963b7dae6cc8c8b2.jpg, createdBy=11b55161224, createdName=146b8afcm93(暂无昵称), createdTime=Thu Mar 18 19:51:40 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917595, encodeId=961b91e59517, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:23 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
2021-07-09 刘东泽

好

74 0
[GetPortalCommentsPageByObjectIdResponse(id=1069487, encodeId=ff06106948e25, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24d05619594, createdName=ms3000000366766127, createdTime=Fri Nov 12 09:02:34 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997961, encodeId=1c7b99e961dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpliahBB2LdGxCRcnBjmrmZvEg8kjSybd5bDqSsQEljwtJOMsOjT6IjU91bX5antfPt5tHIv1kf7TgI/0, createdBy=bb9a2046117, createdName=刘东泽, createdTime=Fri Jul 09 13:24:38 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949322, encodeId=573494932280, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/744f639c0ac24549ab1e0c4fbb6876ed/9afc870f9e0d45a0963b7dae6cc8c8b2.jpg, createdBy=11b55161224, createdName=146b8afcm93(暂无昵称), createdTime=Thu Mar 18 19:51:40 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917595, encodeId=961b91e59517, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:23 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
2021-03-18 146b8afcm93(暂无昵称)

好

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1069487, encodeId=ff06106948e25, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24d05619594, createdName=ms3000000366766127, createdTime=Fri Nov 12 09:02:34 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997961, encodeId=1c7b99e961dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpliahBB2LdGxCRcnBjmrmZvEg8kjSybd5bDqSsQEljwtJOMsOjT6IjU91bX5antfPt5tHIv1kf7TgI/0, createdBy=bb9a2046117, createdName=刘东泽, createdTime=Fri Jul 09 13:24:38 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949322, encodeId=573494932280, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210701/744f639c0ac24549ab1e0c4fbb6876ed/9afc870f9e0d45a0963b7dae6cc8c8b2.jpg, createdBy=11b55161224, createdName=146b8afcm93(暂无昵称), createdTime=Thu Mar 18 19:51:40 CST 2021, time=2021-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=917595, encodeId=961b91e59517, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJjdkFuFT9DxkzjiaO5tOZlWvxUdRETwQ5UJ0YfHLz4PJtLpWPTfJjwYBRzhz9OXLQAPH9LYibmER8A/132, createdBy=5d2a5176562, createdName=146e9e94m10(暂无昵称), createdTime=Sun Jan 17 23:28:23 CST 2021, time=2021-01-17, status=1, ipAttribution=)]
2021-01-17 146e9e94m10(暂无昵称)

好

71 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肾内科指南

肾脏移植后抗体介导排斥反应的推荐治疗方法：移植学会工作组的2019年专家共识

相关指南

科室

工具

服务